{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T03:14:47Z","timestamp":1788146087148,"version":"build-2803163510"},"reference-count":93,"publisher":"Walter de Gruyter GmbH","issue":"4","license":[{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Bone marrow transplantation (BMT) has traditionally been viewed as a curative strategy for hematologic malignancies through replacement of the diseased hematopoietic system. However, accumulating evidence indicates that BMT represents a far more profound biological process: an enforced collapse and subsequent reconstruction of the hematopoietic and immune system. This process provides a unique human model to investigate how immune homeostasis can be reprogrammed beyond physiological conditions. Importantly, post-transplant immunity does not revert to a pre-existing state but instead converges on a newly defined equilibrium shaped by conditioning-induced injury, donor-recipient immune interactions, stromal regeneration, and therapeutic interventions. In this review, we conceptualize BMT as an immune reset and synthesize emerging insights into the mechanisms that govern tolerance reinstallation and immune stability after transplantation. By reframing BMT as a model of immune reset rather than simple immune reconstitution, we highlight general principles of immune homeostasis restoration that extend beyond transplantation and may inform therapeutic strategies for autoimmunity, immune aging, and immune-mediated diseases.<\/jats:p>","DOI":"10.1515\/mr-2026-0021","type":"journal-article","created":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T05:55:55Z","timestamp":1781502955000},"page":"273-286","source":"Crossref","is-referenced-by-count":0,"title":["Immune reset: what do we learn from bone marrow transplantation"],"prefix":"10.1515","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3851-3656","authenticated-orcid":false,"given":"Huidong","family":"Guo","sequence":"first","affiliation":[{"name":"Peking University People\u2019s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Collaborative Innovation Center of Hematology, Peking University , Beijing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2145-6643","authenticated-orcid":false,"given":"Xiao-Jun","family":"Huang","sequence":"additional","affiliation":[{"name":"Peking University People\u2019s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Collaborative Innovation Center of Hematology, Peking University , Beijing , China"},{"name":"Peking-Tsinghua Center for Life Sciences, Academy for Advanced Interdisciplinary Studies, Peking University , Beijing , China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2026,6,16]]},"reference":[{"key":"2026083102570585618_j_mr-2026-0021_ref_001","doi-asserted-by":"crossref","unstructured":"Sevilla, J, Fern\u00e1ndez-Plaza, S, Diaz, MA, Madero, L. Paediatric disease working party of the EBMT. Hematopoietic transplantation for bone marrow failure syndromes and thalassemia. Bone Marrow Transplant 2005;35:S17\u201321. https:\/\/doi.org\/10.1038\/sj.bmt.1704838.","DOI":"10.1038\/sj.bmt.1704838"},{"key":"2026083102570585618_j_mr-2026-0021_ref_002","doi-asserted-by":"crossref","unstructured":"Chabannon, C, Kuball, J, Bondanza, A, Dazzi, F, Pedrazzoli, P, Toubert, A, et al.. Hematopoietic stem cell transplantation in its 60s: a platform for cellular therapies. Sci Transl Med 2018;10:eaap9630. https:\/\/doi.org\/10.1126\/scitranslmed.aap9630.","DOI":"10.1126\/scitranslmed.aap9630"},{"key":"2026083102570585618_j_mr-2026-0021_ref_003","doi-asserted-by":"crossref","unstructured":"Kanakry, CG, Fuchs, EJ, Luznik, L. Modern approaches to HLA-Haploidentical blood or marrow transplantation. Nat Rev Clin Oncol 2016;13:10\u201324. https:\/\/doi.org\/10.1038\/nrclinonc.2015.128.","DOI":"10.1038\/nrclinonc.2015.128"},{"key":"2026083102570585618_j_mr-2026-0021_ref_004","doi-asserted-by":"crossref","unstructured":"Guo, H, Xu, ZL, Pei, XY, Zhao, XY, Huang, XJ. HLA haploidentical HSCT: from immune imbalance to a platform for immune homeostasis restoration. Immun Inflamm 2025;1:12. https:\/\/doi.org\/10.1007\/s44466-025-00008-y.","DOI":"10.1007\/s44466-025-00008-y"},{"key":"2026083102570585618_j_mr-2026-0021_ref_005","doi-asserted-by":"crossref","unstructured":"Swart, JF, Delemarre, EM, van Wijk, F, Boelens, J-J, Kuball, J, van Laar, JM, et al.. Haematopoietic stem cell transplantation for autoimmune diseases. Nat Rev Rheumatol 2017;13:244\u201356. https:\/\/doi.org\/10.1038\/nrrheum.2017.7.","DOI":"10.1038\/nrrheum.2017.7"},{"key":"2026083102570585618_j_mr-2026-0021_ref_006","doi-asserted-by":"crossref","unstructured":"Griffin, JM, Healy, FM, Dahal, LN, Floisand, Y, Woolley, JF. Worked to the bone: antibody-based conditioning as the future of transplant biology. J\u00a0Hematol Oncol 2022;15:65. https:\/\/doi.org\/10.1186\/s13045-022-01284-6.","DOI":"10.1186\/s13045-022-01284-6"},{"key":"2026083102570585618_j_mr-2026-0021_ref_007","doi-asserted-by":"crossref","unstructured":"Junt, T, Calzascia, T, Traggiai, E, da Costa, AN, Gergely, P, Schett, G, et al.. Defining immune reset: achieving sustained remission in autoimmune diseases. Nat Rev Immunol 2025;25:528\u201341. https:\/\/doi.org\/10.1038\/s41577-025-01141-w.","DOI":"10.1038\/s41577-025-01141-w"},{"key":"2026083102570585618_j_mr-2026-0021_ref_008","doi-asserted-by":"crossref","unstructured":"Giralt, S, Ballen, K, Rizzo, D, Bacigalupo, A, Horowitz, M, Pasquini, M, et al.. Reduced-intensity conditioning regimen workshop: defining the dose spectrum. report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transplant 2009;15:367\u20139. https:\/\/doi.org\/10.1016\/j.bbmt.2008.12.497.","DOI":"10.1016\/j.bbmt.2008.12.497"},{"key":"2026083102570585618_j_mr-2026-0021_ref_009","doi-asserted-by":"crossref","unstructured":"Gagelmann, N, Kr\u00f6ger, N. Dose intensity for conditioning in allogeneic hematopoietic cell transplantation: can we recommend \u201cwhen and for whom\u201d in 2021? Haematologica 2021;106:1794\u2013804. https:\/\/doi.org\/10.3324\/haematol.2020.268839.","DOI":"10.3324\/haematol.2020.268839"},{"key":"2026083102570585618_j_mr-2026-0021_ref_010","doi-asserted-by":"crossref","unstructured":"Mauch, P, Constine, L, Greenberger, J, Knospe, W, Sullivan, J, Liesveld, JL, et al.. Hematopoietic stem cell compartment: acute and late effects of radiation therapy and chemotherapy. Int J Radiat Oncol 1995;31:1319\u201339. https:\/\/doi.org\/10.1016\/0360-3016(94)00430-s.","DOI":"10.1016\/0360-3016(94)00430-S"},{"key":"2026083102570585618_j_mr-2026-0021_ref_011","doi-asserted-by":"crossref","unstructured":"Zhou, BO, Yue, R, Murphy, MM, Peyer, JG, Morrison, SJ. Leptin-receptor-expressing mesenchymal stromal cells represent the main source of bone formed by adult bone marrow. Cell Stem Cell 2014;15:154\u201368. https:\/\/doi.org\/10.1016\/j.stem.2014.06.008.","DOI":"10.1016\/j.stem.2014.06.008"},{"key":"2026083102570585618_j_mr-2026-0021_ref_012","doi-asserted-by":"crossref","unstructured":"Mizoguchi, T, Pinho, S, Ahmed, J, Kunisaki, Y, Hanoun, M, Mendelson, A, et al.. Osterix marks distinct waves of primitive and definitive stromal progenitors during bone marrow development. Dev Cell 2014;29:340\u20139. https:\/\/doi.org\/10.1016\/j.devcel.2014.03.013.","DOI":"10.1016\/j.devcel.2014.03.013"},{"key":"2026083102570585618_j_mr-2026-0021_ref_013","doi-asserted-by":"crossref","unstructured":"Zhou, BO, Yu, H, Yue, R, Zhao, Z, Rios, JJ, Naveiras, O, et al.. Bone marrow adipocytes promote the regeneration of stem cells and haematopoiesis by secreting SCF. Nat Cell Biol 2017;19:891\u2013903. https:\/\/doi.org\/10.1038\/ncb3570.","DOI":"10.1038\/ncb3570"},{"key":"2026083102570585618_j_mr-2026-0021_ref_014","doi-asserted-by":"crossref","unstructured":"Tikhonova, AN, Dolgalev, I, Hu, H, Sivaraj, KK, Hoxha, E, Cuesta-Dom\u00ednguez, \u00c1, et al.. The bone marrow microenvironment at single-cell resolution. Nature 2019;569:222\u20138. https:\/\/doi.org\/10.1038\/s41586-019-1104-8.","DOI":"10.1038\/s41586-019-1104-8"},{"key":"2026083102570585618_j_mr-2026-0021_ref_015","doi-asserted-by":"crossref","unstructured":"Pinho, S, Frenette, PS. Haematopoietic stem cell activity and interactions with the niche. Nat Rev Mol Cell Biol 2019;20:303\u201320. https:\/\/doi.org\/10.1038\/s41580-019-0103-9.","DOI":"10.1038\/s41580-019-0103-9"},{"key":"2026083102570585618_j_mr-2026-0021_ref_016","doi-asserted-by":"crossref","unstructured":"Xing, T, Hu, LJ, Zhao, HY, Li, CY, Wang, ZK, Shen, MZ, et al.. Bone marrow endothelial progenitor cells remodelling facilitates normal hematopoiesis during acute myeloid leukemia complete remission. Nat Commun 2024;15:10832. https:\/\/doi.org\/10.1038\/s41467-024-55051-x.","DOI":"10.1038\/s41467-024-55051-x"},{"key":"2026083102570585618_j_mr-2026-0021_ref_017","doi-asserted-by":"crossref","unstructured":"Chandra, S, Chandrakasan, S, D\u00e1vila Salda\u00f1a, BJ, Bleesing, JJ, Jordan, MB, Kumar, AR, et al.. Experience with a reduced toxicity allogeneic transplant regimen for non-CGD primary immune deficiencies requiring myeloablation. J\u00a0Clin Immunol 2021;41:89\u201398. https:\/\/doi.org\/10.1007\/s10875-020-00888-2.","DOI":"10.1007\/s10875-020-00888-2"},{"key":"2026083102570585618_j_mr-2026-0021_ref_018","doi-asserted-by":"crossref","unstructured":"Allen, CE, Marsh, R, Dawson, P, Bollard, CM, Shenoy, S, Roehrs, P, et al.. Reduced-intensity conditioning for hematopoietic cell transplant for HLH and primary immune deficiencies. Blood 2018;132:1438\u201351. https:\/\/doi.org\/10.1182\/blood-2018-01-828277.","DOI":"10.1182\/blood-2018-01-828277"},{"key":"2026083102570585618_j_mr-2026-0021_ref_019","doi-asserted-by":"crossref","unstructured":"Eapen, M, Brazauskas, R, Walters, MC, Bernaudin, F, Bo-Subait, K, Fitzhugh, CD, et al.. Effect of donor type and conditioning regimen intensity on allogeneic transplantation outcomes in patients with sickle cell disease: a retrospective multicentre, cohort study. Lancet Haematol 2019;6:e585\u201396. https:\/\/doi.org\/10.1016\/s2352-3026(19)30154-1.","DOI":"10.1016\/S2352-3026(19)30154-1"},{"key":"2026083102570585618_j_mr-2026-0021_ref_020","doi-asserted-by":"crossref","unstructured":"Harris, AC, Boelens, JJ, Ahn, KW, Fei, M, Abraham, A, Artz, A, et al.. Comparison of pediatric allogeneic transplant outcomes using myeloablative busulfan with cyclophosphamide or fludarabine. Blood Adv 2018;2:1198\u2013206. https:\/\/doi.org\/10.1182\/bloodadvances.2018016956.","DOI":"10.1182\/bloodadvances.2018016956"},{"key":"2026083102570585618_j_mr-2026-0021_ref_021","doi-asserted-by":"crossref","unstructured":"Slatter, MA, Boztug, H, P\u00f6tschger, U, Sykora, KW, Lankester, A, Yaniv, I, et al.. Treosulfan-based conditioning regimens for allogeneic haematopoietic stem cell transplantation in children with non-malignant diseases. Bone Marrow Transplant 2015;50:1536\u201341. https:\/\/doi.org\/10.1038\/bmt.2015.171.","DOI":"10.1038\/bmt.2015.171"},{"key":"2026083102570585618_j_mr-2026-0021_ref_022","doi-asserted-by":"crossref","unstructured":"Albert, MH, Slatter, MA, Gennery, AR, G\u00fcng\u00f6r, T, Bakunina, K, Markovitch, B, et al.. Hematopoietic stem cell transplantation for Wiskott-Aldrich syndrome: an EBMT inborn errors working party analysis. Blood 2022;139:2066\u201379. https:\/\/doi.org\/10.1182\/blood.2021014687.","DOI":"10.1182\/blood.2021014687"},{"key":"2026083102570585618_j_mr-2026-0021_ref_023","doi-asserted-by":"crossref","unstructured":"Pang, WW, Czechowicz, A, Logan, AC, Bhardwaj, R, Poyser, J, Park, CY, et al.. Anti-CD117 antibody depletes normal and myelodysplastic syndrome human hematopoietic stem cells in xenografted mice. Blood 2019;133:2069\u201378. https:\/\/doi.org\/10.1182\/blood-2018-06-858159.","DOI":"10.1182\/blood-2018-06-858159"},{"key":"2026083102570585618_j_mr-2026-0021_ref_024","doi-asserted-by":"crossref","unstructured":"Kwon, H-S, Logan, AC, Chhabra, A, Pang, WW, Czechowicz, A, Tate, K, et al.. Anti-human CD117\u00a0antibody-mediated bone marrow niche clearance in nonhuman Primates and humanized NSG mice. Blood 2019;133:2104\u20138. https:\/\/doi.org\/10.1182\/blood-2018-06-853879.","DOI":"10.1182\/blood-2018-06-853879"},{"key":"2026083102570585618_j_mr-2026-0021_ref_025","doi-asserted-by":"crossref","unstructured":"Chhabra, A, Ring, AM, Weiskopf, K, Schnorr, PJ, Gordon, S, Le, AC, et al.. Hematopoietic stem cell transplantation in immunocompetent hosts without radiation or chemotherapy. Sci Transl Med 2016;8:351ra105. https:\/\/doi.org\/10.1126\/scitranslmed.aae0501.","DOI":"10.1126\/scitranslmed.aae0501"},{"key":"2026083102570585618_j_mr-2026-0021_ref_026","doi-asserted-by":"crossref","unstructured":"Srikanthan, MA, Humbert, O, Haworth, KG, Ironside, C, Rajawat, YS, Blazar, BR, et al.. Effective multi-lineage engraftment in a mouse model of Fanconi Anemia using non-genotoxic antibody-based conditioning. Mol Ther Meth Clin Dev 2020;17:455\u201364. https:\/\/doi.org\/10.1016\/j.omtm.2020.02.001.","DOI":"10.1016\/j.omtm.2020.02.001"},{"key":"2026083102570585618_j_mr-2026-0021_ref_027","doi-asserted-by":"crossref","unstructured":"Czechowicz, A, Palchaudhuri, R, Scheck, A, Hu, Y, Hoggatt, J, Saez, B, et al.. Selective hematopoietic stem cell ablation using CD117-antibody-drug-conjugates enables safe and effective transplantation with immunity preservation. Nat Commun 2019;10:617. https:\/\/doi.org\/10.1038\/s41467-018-08201-x.","DOI":"10.1038\/s41467-018-08201-x"},{"key":"2026083102570585618_j_mr-2026-0021_ref_028","doi-asserted-by":"crossref","unstructured":"Russell, AL, Prince, C, Lundgren, TS, Knight, KA, Denning, G, Alexander, JS, et al.. Non-genotoxic conditioning facilitates hematopoietic stem cell gene therapy for hemophilia a using bioengineered factor VIII. Mol Ther Meth Clin Dev 2021;21:710\u201327. https:\/\/doi.org\/10.1016\/j.omtm.2021.04.016.","DOI":"10.1016\/j.omtm.2021.04.016"},{"key":"2026083102570585618_j_mr-2026-0021_ref_029","doi-asserted-by":"crossref","unstructured":"Uchida, N, Stasula, U, Demirci, S, Germino-Watnick, P, Hinds, M, Le, A, et al.. Fertility-preserving myeloablative conditioning using single-dose CD117 antibody-drug conjugate in a Rhesus gene therapy model. Nat Commun 2023;14:6291. https:\/\/doi.org\/10.1038\/s41467-023-41153-5.","DOI":"10.1038\/s41467-023-41153-5"},{"key":"2026083102570585618_j_mr-2026-0021_ref_030","doi-asserted-by":"crossref","unstructured":"Saha, A, Hyzy, S, Lamothe, T, Hammond, K, Clark, N, Lanieri, L, et al.. A CD45-targeted antibody-drug conjugate successfully conditions for allogeneic hematopoietic stem cell transplantation in mice. Blood 2022;139:1743\u201359. https:\/\/doi.org\/10.1182\/blood.2021012366.","DOI":"10.1182\/blood.2021012366"},{"key":"2026083102570585618_j_mr-2026-0021_ref_031","doi-asserted-by":"crossref","unstructured":"Pala, F, Corsino, C, Calzoni, E, Villa, A, Pittaluga, S, Palchaudhuri, R, et al.. Transplantation after CD45-ADC corrects Rag1 immunodeficiency in congenic and haploidentical settings. J\u00a0Allergy Clin Immunol 2024;153:341\u20138.e3. https:\/\/doi.org\/10.1016\/j.jaci.2023.07.017.","DOI":"10.1016\/j.jaci.2023.07.017"},{"key":"2026083102570585618_j_mr-2026-0021_ref_032","doi-asserted-by":"crossref","unstructured":"Saha, A, Palchaudhuri, R, Lanieri, L, Hyzy, S, Riddle, MJ, Panthera, J, et al.. Alloengraftment without significant toxicity or GVHD in CD45\u00a0antibody-drug conjugate\u2013conditioned Fanconi Anemia mice. Blood 2024;143:2201\u201316. https:\/\/doi.org\/10.1182\/blood.2023023549.","DOI":"10.1182\/blood.2023023549"},{"key":"2026083102570585618_j_mr-2026-0021_ref_033","doi-asserted-by":"crossref","unstructured":"Persaud, SP, Ritchey, JK, Kim, S, Lim, S, Ruminski, PG, Cooper, ML, et al.. Antibody-drug conjugates plus Janus kinase inhibitors enable MHC-mismatched allogeneic hematopoietic stem cell transplantation. J\u00a0Clin Investig 2021;131:e145501. https:\/\/doi.org\/10.1172\/jci145501.","DOI":"10.1172\/JCI145501"},{"key":"2026083102570585618_j_mr-2026-0021_ref_034","doi-asserted-by":"crossref","unstructured":"Muffly, L, Lee, CJ, Gandhi, A, Varma, A, Scott, BL, Patel, SS, et al.. Nonmyeloablative conditioning combined with the anti-CD117 antibody briquilimab in older adults with high-risk AML and MDS. Blood 2026;147:2610\u201320. https:\/\/doi.org\/10.1182\/blood.2025031858.","DOI":"10.1182\/blood.2025031858"},{"key":"2026083102570585618_j_mr-2026-0021_ref_035","doi-asserted-by":"crossref","unstructured":"Agarwal, R, Bertaina, A, Soco, C, Long-Boyle, JR, Saini, G, Kunte, N, et al.. Irradiation- and busulfan-free stem cell transplantation in Fanconi Anemia using an anti-CD117 antibody: a phase 1b trial. Nat Med 2025;31:3183\u201390. https:\/\/doi.org\/10.1038\/s41591-025-03817-1.","DOI":"10.1038\/s41591-025-03817-1"},{"key":"2026083102570585618_j_mr-2026-0021_ref_036","doi-asserted-by":"crossref","unstructured":"Myburgh, R, Kiefer, JD, Russkamp, NF, Magnani, CF, Nu\u00f1ez, N, Simonis, A, et al.. Anti-human CD117 CAR T-cells efficiently eliminate healthy and malignant CD117-expressing hematopoietic cells. Leukemia 2020;34:2688\u2013703. https:\/\/doi.org\/10.1038\/s41375-020-0818-9.","DOI":"10.1038\/s41375-020-0818-9"},{"key":"2026083102570585618_j_mr-2026-0021_ref_037","doi-asserted-by":"crossref","unstructured":"Hu, Y, Zhang, M, Yang, T, Mo, Z, Wei, G, Jing, R, et al.. Sequential CD7 CAR T-cell therapy and allogeneic HSCT without GVHD prophylaxis. N\u00a0Engl J Med 2024;390:1467\u201380. https:\/\/doi.org\/10.1056\/nejmoa2313812.","DOI":"10.1056\/NEJMoa2313812"},{"key":"2026083102570585618_j_mr-2026-0021_ref_038","doi-asserted-by":"crossref","unstructured":"Zhang, C, Kong, PY, Li, S, Chen, T, Ni, X, Li, Y, et al.. Donor-derived CAR-T cells serve as a reduced-intensity conditioning regimen for haploidentical stem cell transplantation in treatment of relapsed\/refractory acute lymphoblastic leukemia: case report and review of the literature. J\u00a0Immunother 2018;41:306\u201311. https:\/\/doi.org\/10.1097\/cji.0000000000000233.","DOI":"10.1097\/CJI.0000000000000233"},{"key":"2026083102570585618_j_mr-2026-0021_ref_039","doi-asserted-by":"crossref","unstructured":"Yang, F, Shi, H, Xu, T, Liu, R, Lei, Y, Li, R, et al.. Allogeneic stem cell transplantation combined with conditioning regimen including donor-derived CAR-T cells for refractory\/relapsed B-cell lymphoma. Bone Marrow Transplant 2023;58:440\u20132. https:\/\/doi.org\/10.1038\/s41409-022-01903-3.","DOI":"10.1038\/s41409-022-01903-3"},{"key":"2026083102570585618_j_mr-2026-0021_ref_086","doi-asserted-by":"crossref","unstructured":"George, BM, Kao, KS, Kwon, H-S, Velasco, BJ, Poyser, J, Chen, A, et al.. Antibody conditioning enables MHC-mismatched hematopoietic stem cell transplants and organ graft tolerance. Cell Stem Cell 2019;25:185\u201392.e3. https:\/\/doi.org\/10.1016\/j.stem.2019.05.018.","DOI":"10.1016\/j.stem.2019.05.018"},{"key":"2026083102570585618_j_mr-2026-0021_ref_087","doi-asserted-by":"crossref","unstructured":"Yeung, J, Liao, A, Shaw, M, Silva, S, Vetharoy, W, Rico, DL, et al.. Anti-CD45 PBD-based antibody-drug conjugates are effective targeted conditioning agents for gene therapy and stem cell transplant. Mol Ther 2024;32:1672\u201386. https:\/\/doi.org\/10.1016\/j.ymthe.2024.03.032.","DOI":"10.1016\/j.ymthe.2024.03.032"},{"key":"2026083102570585618_j_mr-2026-0021_ref_088","doi-asserted-by":"crossref","unstructured":"Palchaudhuri, R, Saez, B, Hoggatt, J, Schajnovitz, A, Sykes, DB, Tate, TA, et al.. Non-genotoxic conditioning for hematopoietic stem cell transplantation using a hematopoietic-cell-specific internalizing immunotoxin. Nat Biotechnol 2016;34:738\u201345. https:\/\/doi.org\/10.1038\/nbt.3584.","DOI":"10.1038\/nbt.3584"},{"key":"2026083102570585618_j_mr-2026-0021_ref_089","doi-asserted-by":"crossref","unstructured":"Castiello, MC, Bosticardo, M, Sacchetti, N, Calzoni, E, Fontana, E, Yamazaki, Y, et al.. Efficacy and safety of anti-CD45\u2013saporin as conditioning agent for RAG deficiency. J\u00a0Allergy Clin Immunol 2021;147:309\u201320.e6. https:\/\/doi.org\/10.1016\/j.jaci.2020.04.033.","DOI":"10.1016\/j.jaci.2020.04.033"},{"key":"2026083102570585618_j_mr-2026-0021_ref_090","doi-asserted-by":"crossref","unstructured":"Li, Z, Czechowicz, A, Scheck, A, Rossi, DJ, Murphy, PM. Hematopoietic chimerism and donor-specific skin allograft tolerance after non-genotoxic CD117 antibody-drug-conjugate conditioning in MHC-mismatched allotransplantation. Nat Commun 2019;10:616. https:\/\/doi.org\/10.1038\/s41467-018-08202-w.","DOI":"10.1038\/s41467-018-08202-w"},{"key":"2026083102570585618_j_mr-2026-0021_ref_091","doi-asserted-by":"crossref","unstructured":"Persaud, SP, Yelamali, AR, Ritchey, JK, DiPersio, JF. Conditioning with anti-CD47 and anti-CD117 plus JAK inhibition enables toxic payload-free allogeneic transplantation. Blood Adv 2024;8:4502\u20136. https:\/\/doi.org\/10.1182\/bloodadvances.2023012457.","DOI":"10.1182\/bloodadvances.2023012457"},{"key":"2026083102570585618_j_mr-2026-0021_ref_092","doi-asserted-by":"crossref","unstructured":"Arai, Y, Choi, U, Corsino, CI, Koontz, SM, Tajima, M, Sweeney, CL, et al.. Myeloid conditioning with c-kit-targeted CAR-T cells enables donor stem cell engraftment. Mol Ther 2018;26:1181\u201397. https:\/\/doi.org\/10.1016\/j.ymthe.2018.03.003.","DOI":"10.1016\/j.ymthe.2018.03.003"},{"key":"2026083102570585618_j_mr-2026-0021_ref_093","doi-asserted-by":"crossref","unstructured":"Li, Z, An, N, Yang, K, Meng, F, Xu, T, Peng, X, et al.. Donor CD7 chimeric antigen receptor T\u00a0cell bridging to allogeneic hematopoietic stem cell transplantation for T\u00a0cell hematologic malignancy. Transplant Cell Ther 2023;29:167\u201373. https:\/\/doi.org\/10.1016\/j.jtct.2022.11.013.","DOI":"10.1016\/j.jtct.2022.11.013"},{"key":"2026083102570585618_j_mr-2026-0021_ref_040","doi-asserted-by":"crossref","unstructured":"Ashby, KM, Hogquist, KA. A guide to thymic selection of T\u00a0cells. Nat Rev Immunol 2024;24:103\u201317. https:\/\/doi.org\/10.1038\/s41577-023-00911-8.","DOI":"10.1038\/s41577-023-00911-8"},{"key":"2026083102570585618_j_mr-2026-0021_ref_041","doi-asserted-by":"crossref","unstructured":"Guo, H, Guo, L, Wang, B, Jiang, X, Wu, Z, Mo, XD, et al.. Distinct immune homeostasis remodeling patterns after HLA-matched and haploidentical transplantation. Adv Sci 2024;11:e2400544. https:\/\/doi.org\/10.1002\/advs.202400544.","DOI":"10.1002\/advs.202400544"},{"key":"2026083102570585618_j_mr-2026-0021_ref_042","doi-asserted-by":"crossref","unstructured":"Hauri-Hohl, MM, Zuklys, S, Keller, MP, Jeker, LT, Barthlott, T, Moon, AM, et al.. TGF-\u03b2 signaling in thymic epithelial cells regulates thymic involution and postirradiation reconstitution. Blood 2008;112:626\u201334. https:\/\/doi.org\/10.1182\/blood-2007-10-115618.","DOI":"10.1182\/blood-2007-10-115618"},{"key":"2026083102570585618_j_mr-2026-0021_ref_043","doi-asserted-by":"crossref","unstructured":"Horie, K, Namiki, K, Kinoshita, K, Miyauchi, M, Ishikawa, T, Hayama, M, et al.. Acute irradiation causes a long-term disturbance in the heterogeneity and gene expression profile of medullary thymic epithelial cells. Front Immunol 2023;14:1186154. https:\/\/doi.org\/10.3389\/fimmu.2023.1186154.","DOI":"10.3389\/fimmu.2023.1186154"},{"key":"2026083102570585618_j_mr-2026-0021_ref_044","doi-asserted-by":"crossref","unstructured":"Alawam, AS, Cosway, EJ, James, KD, Lucas, B, Bacon, A, Parnell, SM, et al.. Failures in thymus medulla regeneration during immune recovery cause tolerance loss and prime recipients for auto-GVHD. J\u00a0Exp Med 2022;219:e20211239. https:\/\/doi.org\/10.1084\/jem.20211239.","DOI":"10.1084\/jem.20211239"},{"key":"2026083102570585618_j_mr-2026-0021_ref_045","doi-asserted-by":"crossref","unstructured":"Dertschnig, S, Hauri-Hohl, MM, Vollmer, M, Holl\u00e4nder, GA, Krenger, W. Impaired thymic expression of tissue-restricted antigens licenses the de novo generation of autoreactive CD4+ T\u00a0cells in acute GVHD. Blood 2015;125:2720\u20133. https:\/\/doi.org\/10.1182\/blood-2014-08-597245.","DOI":"10.1182\/blood-2014-08-597245"},{"key":"2026083102570585618_j_mr-2026-0021_ref_046","doi-asserted-by":"crossref","unstructured":"Dertschnig, S, Nusspaumer, G, Ivanek, R, Hauri-Hohl, MM, Holl\u00e4nder, GA, Krenger, W. Epithelial cytoprotection sustains ectopic expression of tissue-restricted antigens in the thymus during murine acute GVHD. Blood 2013;122:837\u201341. https:\/\/doi.org\/10.1182\/blood-2012-12-474759.","DOI":"10.1182\/blood-2012-12-474759"},{"key":"2026083102570585618_j_mr-2026-0021_ref_047","doi-asserted-by":"crossref","unstructured":"Klein, L, Petrozziello, E. Antigen presentation for central tolerance induction. Nat Rev Immunol 2025;25:57\u201372. https:\/\/doi.org\/10.1038\/s41577-024-01076-8.","DOI":"10.1038\/s41577-024-01076-8"},{"key":"2026083102570585618_j_mr-2026-0021_ref_048","doi-asserted-by":"crossref","unstructured":"Dertschnig, S, Evans, P, Santos e Sousa, P, Manzo, T, Ferrer, IR, Stauss, HJ, et al.. Graft-versus-host disease reduces lymph node display of tissue-restricted self-antigens and promotes autoimmunity. J\u00a0Clin Investig 2020;130:1896\u2013911. https:\/\/doi.org\/10.1172\/jci133102.","DOI":"10.1172\/JCI133102"},{"key":"2026083102570585618_j_mr-2026-0021_ref_049","doi-asserted-by":"crossref","unstructured":"Wu, N, Ding, W, Wu, J, Ling, M, Yue, K, Cheng, C, et al.. MHC disparity hampers thymus-dependent T-cell recovery post-hematopoietic transplantation through dysregulation of TGF-\u03b21 and LRP6 pathways. Haematologica 2026;111:892\u2013905. https:\/\/doi.org\/10.3324\/haematol.2025.288464.","DOI":"10.3324\/haematol.2025.288464"},{"key":"2026083102570585618_j_mr-2026-0021_ref_050","doi-asserted-by":"crossref","unstructured":"Guo, H, Li, R, Wang, M, Hou, Y, Liu, S, Peng, T, et al.. Multiomics analysis identifies SOCS1 as restraining T\u00a0cell activation and preventing graft-versus-host disease. Adv Sci 2022;9:e2200978. https:\/\/doi.org\/10.1002\/advs.202200978.","DOI":"10.1002\/advs.202200978"},{"key":"2026083102570585618_j_mr-2026-0021_ref_051","doi-asserted-by":"crossref","unstructured":"Ruzek, MC, Waire, JS, Hopkins, D, LaCorcia, G, Sullivan, J, Roberts, BL, et al.. Characterization of in\u00a0vitro antimurine thymocyte globulin\u2013induced regulatory T\u00a0cells that inhibit graft-versus-host disease in\u00a0vivo. Blood 2008;111:1726\u201334. https:\/\/doi.org\/10.1182\/blood-2007-08-106526.","DOI":"10.1182\/blood-2007-08-106526"},{"key":"2026083102570585618_j_mr-2026-0021_ref_052","doi-asserted-by":"crossref","unstructured":"Wachsmuth, LP, Patterson, MT, Eckhaus, MA, Venzon, DJ, Gress, RE, Kanakry, CG, et al.. Posttransplantation cyclophosphamide prevents graft-versus-host disease by inducing alloreactive T\u00a0cell dysfunction and suppression. J\u00a0Clin Investig 2019;129:2357\u201373. https:\/\/doi.org\/10.1172\/jci124218.","DOI":"10.1172\/JCI124218"},{"key":"2026083102570585618_j_mr-2026-0021_ref_053","doi-asserted-by":"crossref","unstructured":"Hultborn, R, Albertsson, P, Ottosson, S, Warnhammar, E, Palm, \u00c5, Palm, S, et al.. Radiosensitivity: gender and order of administration of G-CSF, an experimental study in mice. Radiat Res 2019;191:335\u201341. https:\/\/doi.org\/10.1667\/rr15038.1.","DOI":"10.1667\/RR15038.1"},{"key":"2026083102570585618_j_mr-2026-0021_ref_054","doi-asserted-by":"crossref","unstructured":"Zhao, H, Guo, M, Sun, X, Sun, W, Hu, H, Wei, L, et al.. Effects of recombinant human granulocyte colony-stimulating factor on central and peripheral T lymphocyte reconstitution after sublethal irradiation in mice. J\u00a0Radiat Res 2013;54:83\u201391. https:\/\/doi.org\/10.1093\/jrr\/rrs082.","DOI":"10.1093\/jrr\/rrs082"},{"key":"2026083102570585618_j_mr-2026-0021_ref_055","doi-asserted-by":"crossref","unstructured":"Guo, H, Jiang, X, Wu, Z, Zhang, F, Huang, Q, Wang, B, et al.. Post-transplant G-CSF restores T\u00a0cell homeostasis by inhibiting alloreactive T\u00a0cells and promoting thymic regeneration. Blood 2024;144:2013. https:\/\/doi.org\/10.1182\/blood-2024-200581.","DOI":"10.1182\/blood-2024-200581"},{"key":"2026083102570585618_j_mr-2026-0021_ref_056","doi-asserted-by":"crossref","unstructured":"Huang, X, Guo, H, Wang, B. CD8+hla-DR+CD27+ t\u00a0cells define a population of naturally occurring regulatory precursors in humans. Blood 2025;146:4080. https:\/\/doi.org\/10.1182\/blood-2025-4080.","DOI":"10.1182\/blood-2025-4080"},{"key":"2026083102570585618_j_mr-2026-0021_ref_057","doi-asserted-by":"crossref","unstructured":"Nemazee, D. Mechanisms of central tolerance for B\u00a0cells. Nat Rev Immunol 2017;17:281\u201394. https:\/\/doi.org\/10.1038\/nri.2017.19.","DOI":"10.1038\/nri.2017.19"},{"key":"2026083102570585618_j_mr-2026-0021_ref_058","doi-asserted-by":"crossref","unstructured":"Shono, Y, Ueha, S, Wang, Y, Abe, J, Kurachi, M, Matsuno, Y, et al.. Bone marrow graft-versus-host disease: early destruction of hematopoietic niche after MHC-mismatched hematopoietic stem cell transplantation. Blood 2010;115:5401\u201311. https:\/\/doi.org\/10.1182\/blood-2009-11-253559.","DOI":"10.1182\/blood-2009-11-253559"},{"key":"2026083102570585618_j_mr-2026-0021_ref_059","doi-asserted-by":"crossref","unstructured":"Nakamori, Y, Liu, B, Ohishi, K, Suzuki, K, Ino, K, Matsumoto, T, et al.. Human bone marrow stromal cells simultaneously support B and T\/NK lineage development from human haematopoietic progenitors: a principal role for flt3 ligand in lymphopoiesis. Br J Haematol 2012;157:674\u201386. https:\/\/doi.org\/10.1111\/j.1365-2141.2012.09109.x.","DOI":"10.1111\/j.1365-2141.2012.09109.x"},{"key":"2026083102570585618_j_mr-2026-0021_ref_060","doi-asserted-by":"crossref","unstructured":"Corfe, SA, Paige, CJ. The many roles of IL-7 in B\u00a0cell development; mediator of survival, proliferation and differentiation. Semin Immunol 2012;24:198\u2013208. https:\/\/doi.org\/10.1016\/j.smim.2012.02.001.","DOI":"10.1016\/j.smim.2012.02.001"},{"key":"2026083102570585618_j_mr-2026-0021_ref_061","doi-asserted-by":"crossref","unstructured":"D\u2019Apuzzo, M, Rolink, A, Loetscher, M, Hoxie, JA, Clark-Lewis, I, Melchers, F, et al.. The chemokine SDF-1, stromal cell-derived factor 1, attracts early stage B\u00a0cell precursors via the chemokine receptor CXCR4. Eur J Immunol 1997;27:1788\u201393. https:\/\/doi.org\/10.1002\/eji.1830270729.","DOI":"10.1002\/eji.1830270729"},{"key":"2026083102570585618_j_mr-2026-0021_ref_062","doi-asserted-by":"crossref","unstructured":"Talekar, MK, Olson, T. Immune reconstitution after hematopoietic stem cell transplantation. In: Hematopoietic stem cell transplantation for the pediatric hematologist\/oncologist. Cham: Springer International Publishing; 2017:371\u201383 pp.","DOI":"10.1007\/978-3-319-63146-2_26"},{"key":"2026083102570585618_j_mr-2026-0021_ref_063","doi-asserted-by":"crossref","unstructured":"Zeiser, R, Sarantopoulos, S, Blazar, BR. B-cell targeting in chronic graft-versus-host disease. Blood 2018;131:1399\u2013405. https:\/\/doi.org\/10.1182\/blood-2017-11-784017.","DOI":"10.1182\/blood-2017-11-784017"},{"key":"2026083102570585618_j_mr-2026-0021_ref_064","doi-asserted-by":"crossref","unstructured":"Jin, H, Ni, X, Deng, R, Song, Q, Young, J, Cassady, K, et al.. Antibodies from donor B\u00a0cells perpetuate cutaneous chronic graft-versus-host disease in mice. Blood 2016;127:2249\u201360. https:\/\/doi.org\/10.1182\/blood-2015-09-668145.","DOI":"10.1182\/blood-2015-09-668145"},{"key":"2026083102570585618_j_mr-2026-0021_ref_065","doi-asserted-by":"crossref","unstructured":"Srinivasan, M, Flynn, R, Price, A, Ranger, A, Browning, JL, Taylor, PA, et al.. Donor B-cell alloantibody deposition and germinal center formation are required for the development of murine chronic GVHD and bronchiolitis obliterans. Blood 2012;119:1570\u201380. https:\/\/doi.org\/10.1182\/blood-2011-07-364414.","DOI":"10.1182\/blood-2011-07-364414"},{"key":"2026083102570585618_j_mr-2026-0021_ref_066","doi-asserted-by":"crossref","unstructured":"Yamano, T, Nedjic, J, Hinterberger, M, Steinert, M, Koser, S, Pinto, S, et al.. Thymic B\u00a0cells are licensed to present self antigens for central T\u00a0cell tolerance induction. Immunity 2015;42:1048\u201361. https:\/\/doi.org\/10.1016\/j.immuni.2015.05.013.","DOI":"10.1016\/j.immuni.2015.05.013"},{"key":"2026083102570585618_j_mr-2026-0021_ref_067","doi-asserted-by":"crossref","unstructured":"Perera, J, Zheng, Z, Li, S, Gudjonson, H, Kalinina, O, Benichou, JIC, et al.. Self-antigen-driven thymic B\u00a0cell class switching promotes T\u00a0cell central tolerance. Cell Rep 2016;17:387\u201398. https:\/\/doi.org\/10.1016\/j.celrep.2016.09.011.","DOI":"10.1016\/j.celrep.2016.09.011"},{"key":"2026083102570585618_j_mr-2026-0021_ref_068","doi-asserted-by":"crossref","unstructured":"Martinez, RJ, Breed, ER, Worota, Y, Ashby, KM, Vobo\u0159il, M, Mathes, T, et al.. Type III interferon drives thymic B\u00a0cell activation and regulatory T\u00a0cell generation. Proc Natl Acad Sci U S A 2023;120:e2220120120. https:\/\/doi.org\/10.1073\/pnas.2220120120.","DOI":"10.1073\/pnas.2220120120"},{"key":"2026083102570585618_j_mr-2026-0021_ref_069","doi-asserted-by":"crossref","unstructured":"Lee, DSW, Rojas, OL, Gommerman, JL. B\u00a0cell depletion therapies in autoimmune disease: advances and mechanistic insights. Nat Rev Drug Discov 2021;20:179\u201399. https:\/\/doi.org\/10.1038\/s41573-020-00092-2.","DOI":"10.1038\/s41573-020-00092-2"},{"key":"2026083102570585618_j_mr-2026-0021_ref_070","doi-asserted-by":"crossref","unstructured":"M\u00fcller, F, Taubmann, J, Bucci, L, Wilhelm, A, Bergmann, C, V\u00f6lkl, S, et al.. CD19 CAR T-cell therapy in autoimmune disease\u2014a case series with follow-up. N\u00a0Engl J Med 2024;390:687\u2013700. https:\/\/doi.org\/10.1056\/nejmoa2308917.","DOI":"10.1056\/NEJMoa2308917"},{"key":"2026083102570585618_j_mr-2026-0021_ref_071","doi-asserted-by":"crossref","unstructured":"Wang, X, Wu, X, Tan, B, Zhu, L, Zhang, Y, Lin, L, et al.. Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis. Cell 2024;187:4890\u2013904.e9. https:\/\/doi.org\/10.1016\/j.cell.2024.06.027.","DOI":"10.1016\/j.cell.2024.06.027"},{"key":"2026083102570585618_j_mr-2026-0021_ref_072","doi-asserted-by":"crossref","unstructured":"Stenger, EO, Turnquist, HR, Mapara, MY, Thomson, AW. Dendritic cells and regulation of graft-versus-host disease and graft-versus-leukemia activity. Blood 2012;119:5088\u2013103. https:\/\/doi.org\/10.1182\/blood-2011-11-364091.","DOI":"10.1182\/blood-2011-11-364091"},{"key":"2026083102570585618_j_mr-2026-0021_ref_073","doi-asserted-by":"crossref","unstructured":"Morante-Palacios, O, Fondelli, F, Ballestar, E, Mart\u00ednez-C\u00e1ceres, EM. Tolerogenic dendritic cells in autoimmunity and inflammatory diseases. Trends Immunol 2021;42:59\u201375. https:\/\/doi.org\/10.1016\/j.it.2020.11.001.","DOI":"10.1016\/j.it.2020.11.001"},{"key":"2026083102570585618_j_mr-2026-0021_ref_074","doi-asserted-by":"crossref","unstructured":"Watowich, SS, Liu, YJ. Mechanisms regulating dendritic cell specification and development. Immunol Rev 2010;238:76\u201392. https:\/\/doi.org\/10.1111\/j.1600-065x.2010.00949.x.","DOI":"10.1111\/j.1600-065X.2010.00949.x"},{"key":"2026083102570585618_j_mr-2026-0021_ref_075","doi-asserted-by":"crossref","unstructured":"Duffner, UA, Maeda, Y, Cooke, KR, Reddy, P, Ordemann, R, Liu, C, et al.. Host dendritic cells alone are sufficient to initiate acute graft-versus-host disease. J\u00a0Immunol 2004;172:7393\u20138. https:\/\/doi.org\/10.4049\/jimmunol.172.12.7393.","DOI":"10.4049\/jimmunol.172.12.7393"},{"key":"2026083102570585618_j_mr-2026-0021_ref_076","doi-asserted-by":"crossref","unstructured":"Matte, CC, Liu, J, Cormier, J, Anderson, BE, Athanasiadis, I, Jain, D, et al.. Donor APCs are required for maximal GVHD but not for GVL. Nat Med 2004;10:987\u201392. https:\/\/doi.org\/10.1038\/nm1089.","DOI":"10.1038\/nm1089"},{"key":"2026083102570585618_j_mr-2026-0021_ref_077","doi-asserted-by":"crossref","unstructured":"Duneton, C, Winterberg, PD, Ford, ML. Activation and regulation of alloreactive T\u00a0cell immunity in solid organ transplantation. Nat Rev Nephrol 2022;18:663\u201376. https:\/\/doi.org\/10.1038\/s41581-022-00600-0.","DOI":"10.1038\/s41581-022-00600-0"},{"key":"2026083102570585618_j_mr-2026-0021_ref_078","doi-asserted-by":"crossref","unstructured":"Li, YP, Paczesny, S, Lauret, E, Poirault, S, Bordigoni, P, Mekhloufi, F, et al.. Human mesenchymal stem cells license adult CD34+ hemopoietic progenitor cells to differentiate into regulatory dendritic cells through activation of the notch pathway. J\u00a0Immunol 2008;180:1598\u2013608. https:\/\/doi.org\/10.4049\/jimmunol.180.3.1598.","DOI":"10.4049\/jimmunol.180.3.1598"},{"key":"2026083102570585618_j_mr-2026-0021_ref_079","doi-asserted-by":"crossref","unstructured":"Turnquist, HR, Raimondi, G, Zahorchak, AF, Fischer, RT, Wang, Z, Thomson, AW, et al.. Rapamycin-conditioned dendritic cells are poor stimulators of allogeneic CD4+ T\u00a0cells, but enrich for antigen-specific Foxp3+ T regulatory cells and promote organ transplant tolerance. J\u00a0Immunol 2007;178:7018\u201331. https:\/\/doi.org\/10.4049\/jimmunol.178.11.7018.","DOI":"10.4049\/jimmunol.178.11.7018"},{"key":"2026083102570585618_j_mr-2026-0021_ref_080","doi-asserted-by":"crossref","unstructured":"Sato, K, Eizumi, K, Fukaya, T, Fujita, S, Sato, Y, Takagi, H, et al.. Naturally occurring regulatory dendritic cells regulate murine cutaneous chronic graft-versus-host disease. Blood 2009;113:4780\u20139. https:\/\/doi.org\/10.1182\/blood-2008-10-183145.","DOI":"10.1182\/blood-2008-10-183145"},{"key":"2026083102570585618_j_mr-2026-0021_ref_081","doi-asserted-by":"crossref","unstructured":"Srinivasan, J, Moore, CR, Calindi, A, Helm, BR, Yang, Y, Moore, JF, et al.. The differentiation and function of heterogeneous thymic dendritic cell subsets require signals provided by distinct thymocyte cell types. Nat Immunol 2026;27:265\u201380. https:\/\/doi.org\/10.1038\/s41590-025-02371-9.","DOI":"10.1038\/s41590-025-02371-9"},{"key":"2026083102570585618_j_mr-2026-0021_ref_082","doi-asserted-by":"crossref","unstructured":"Pilat, N, Wekerle, T. Transplantation tolerance through mixed chimerism. Nat Rev Nephrol 2010;6:594\u2013605. https:\/\/doi.org\/10.1038\/nrneph.2010.110.","DOI":"10.1038\/nrneph.2010.110"},{"key":"2026083102570585618_j_mr-2026-0021_ref_083","doi-asserted-by":"crossref","unstructured":"Bonasio, R, Scimone, ML, Schaerli, P, Grabie, N, Lichtman, AH, von Andrian, UH, et al.. Clonal deletion of thymocytes by circulating dendritic cells homing to the thymus. Nat Immunol 2006;7:1092\u2013100. https:\/\/doi.org\/10.1038\/ni1385.","DOI":"10.1038\/ni1385"},{"key":"2026083102570585618_j_mr-2026-0021_ref_084","doi-asserted-by":"crossref","unstructured":"Kawai, T, Cosimi, AB, Spitzer, TR, Tolkoff-Rubin, N, Suthanthiran, M, Saidman, SL, et al.. HLA-mismatched renal transplantation without maintenance immunosuppression. N\u00a0Engl J Med 2008;358:353\u201361. https:\/\/doi.org\/10.1056\/nejmoa071074.","DOI":"10.1056\/NEJMoa071074"},{"key":"2026083102570585618_j_mr-2026-0021_ref_085","doi-asserted-by":"crossref","unstructured":"Chen, YB, Elias, N, Heher, E, McCune, JS, Collier, K, Li, S, et al.. Haploidentical hematopoietic cell and kidney transplantation for hematological malignancies and end-stage renal failure. Blood 2019;134:211\u20135. https:\/\/doi.org\/10.1182\/blood.2019000775.","DOI":"10.1182\/blood.2019000775"}],"container-title":["Medical Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/mr-2026-0021\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/mr-2026-0021\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T02:57:23Z","timestamp":1788145043000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/mr-2026-0021\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,16]]},"references-count":93,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,6,16]]},"published-print":{"date-parts":[[2026,8,24]]}},"alternative-id":["10.1515\/mr-2026-0021"],"URL":"https:\/\/doi.org\/10.1515\/mr-2026-0021","relation":{},"ISSN":["2749-9642"],"issn-type":[{"value":"2749-9642","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,16]]}}}